Gilead Sciences, Inc. (GILD) NASDAQ

138.99

-3.1(-2.18%)

Updated at April 10 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Daniel O'Day	Chairman & Chief Executive Officer	7.14M	1965
Andrew D. Dickinson	Chief Financial Officer	2.73M	1970
Deborah H. Telman	Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary	3.11M	1965
Johanna Mercier	Chief Commercial Officer	3.17M	1970
Linda Slanec Higgins	Senior Vice President of Research, Innovation & Portfolio	0	1962
Flavius Martin	Executive Vice President of Research	0	N/A
Bernard Fine	VP of Oncology & Franchise Head of Early Development	0	N/A
Erin Burkhart	SVP, Controller & Principal Accounting Officer	0	1979
Jacquie Ross	Senior Vice President of Treasury and Investor Relations	0	N/A
Janet Dorling	Senior Vice President of Intercontinental Region & Global Patient Solutions	0	1974
Jyoti K. Mehra	Executive Vice President of Human Resources	0	1976

Name

Title

Pay

Year Born

Daniel O'Day

Chairman & Chief Executive Officer

7.14M

1965

Andrew D. Dickinson

Chief Financial Officer

2.73M

1970

Deborah H. Telman

Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary

3.11M

1965

Johanna Mercier

Chief Commercial Officer

3.17M

1970

Linda Slanec Higgins

Senior Vice President of Research, Innovation & Portfolio

1962

Flavius Martin

Executive Vice President of Research

N/A

Bernard Fine

VP of Oncology & Franchise Head of Early Development

N/A

Erin Burkhart

SVP, Controller & Principal Accounting Officer

1979

Jacquie Ross

Senior Vice President of Treasury and Investor Relations

N/A

Janet Dorling

Senior Vice President of Intercontinental Region & Global Patient Solutions

1974

Jyoti K. Mehra

Executive Vice President of Human Resources

1976

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.